Catalyst Wire Dossier Catalyst Wire Dossier

pimecrolimus ophthalmic suspension

pimecrolimus · Novartis
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for pimecrolimus ophthalmic suspension, covering 2020-05-27 to 2020-05-27. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca [Phase 2]

See pricing